Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (3976)
All Articles published online
|
May 28, 2005 (publication date) through Apr 23, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: |
Fock K, Teo E, Ang T, Chua T, Ng T, Tan Y. Rabeprazole |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v11/i20/3091.htm |
| Number | Citing Articles |
| 1 |
M. Tabib, H. Zolgharnein, M. Mohammadi, M.A. Salari-Aliabadi, A. Qasemi, S. Roshani, H. Rajabi-Maham, F. Frootan. mtDNA variation of the critically endangered hawksbill turtle (Eretmochelys imbricata) nesting on Iranian islands of the Persian Gulf. Genetics and Molecular Research 2011; 10(3): 1499 doi: 10.4238/vol10-3gmr1148
|
| 2 |
Doença do refluxo gastroesofágico: tratamento farmacológico. Revista da Associação Médica Brasileira 2011; 57(6): 617 doi: 10.1590/S0104-42302011000600006
|
| 3 |
Kwong Ming Fock, Tiing Leong Ang, Lean Choo Bee, Edmund Jon Deon Lee. Proton Pump Inhibitors. Clinical Pharmacokinetics 2008; 47(1): 1 doi: 10.2165/00003088-200847010-00001
|
| 4 |
Stefano Pallotta, Fabio Pace, Silvia Marelli. Rabeprazole: a second-generation proton pump inhibitor in the treatment of acid-related disease. Expert Review of Gastroenterology & Hepatology 2008; 2(4): 509 doi: 10.1586/17474124.2.4.509
|
| 5 |
A. EGGLESTON, P. H. KATELARIS, S. NANDURKAR, P. THORPE, G. HOLTMANN. Clinical trial: the treatment of gastro‐oesophageal reflux disease in primary care – prospective randomized comparison of rabeprazole 20 mg with esomeprazole 20 and 40 mg. Alimentary Pharmacology & Therapeutics 2009; 29(9): 967 doi: 10.1111/j.1365-2036.2009.03948.x
|
| 6 |
Victoria P. Y. Tan, Wai M. Wong, Ting K. Cheung, Kam C. Lai, Ivan F. N. Hung, Pierre Chan, Roberta Pang, Benjamin C. Y. Wong. Treatment of non-erosive reflux disease with a proton pump inhibitor in Chinese patients: a randomized controlled trial. Journal of Gastroenterology 2011; 46(7): 906 doi: 10.1007/s00535-011-0402-1
|
| 7 |
Shaojun Shi, Ulrich Klotz. Proton pump inhibitors: an update of their clinical use and pharmacokinetics. European Journal of Clinical Pharmacology 2008; 64(10): 935 doi: 10.1007/s00228-008-0538-y
|
| 8 |
Alia Dadabhai, Frank K Friedenberg. Rabeprazole: a pharmacologic and clinical review for acid-related disorders. Expert Opinion on Drug Safety 2009; 8(1): 119 doi: 10.1517/14740330802622892
|
| 9 |
Kiyoshi Ashida, Yoshikazu Kinoshita, Michio Hongo. Acid-Suppressive Effect of Rabeprazole 5 mg and 10 mg Once Daily by 24-Hour Esophageal pH Monitoring in Patients with Non-erosive Reflux Disease in Japan: A Multicenter, Randomized, Parallel-Group, Double-Blind Pharmacodynamic Study. Digestive Diseases and Sciences 2011; 56(8): 2333 doi: 10.1007/s10620-011-1583-4
|
| 10 |
S. Sahara, M. Sugimoto, T. Uotani, H. Ichikawa, M. Yamade, M. Iwaizumi, T. Yamada, S. Osawa, K. Sugimoto, K. Umemura, H. Miyajima, T. Furuta. Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole. Alimentary Pharmacology & Therapeutics 2013; 38(9): 1129 doi: 10.1111/apt.12492
|
| 11 |
Hao Li, Ling Meng, Fei Liu, Ji-Fu Wei, Yong-Qing Wang. H+/K+-ATPase inhibitors: a patent review. Expert Opinion on Therapeutic Patents 2013; 23(1): 99 doi: 10.1517/13543776.2013.741121
|
| 12 |
Akihito Nagahara, Hiroto Miwa, Daisuke Asaoka, Yuji Shimada, Hitoshi Sasaki, Kenshi Matsumoto, Taro Osada, Mariko Hojo, Sumio Watanabe. Pretreatment prediction of symptom response to proton pump inhibitor therapy. Journal of Gastroenterology and Hepatology 2015; 30(S1): 25 doi: 10.1111/jgh.12744
|
| 13 |
Consuelo L Saccar. The pharmacology of esomeprazole and its role in gastric acid related diseases. Expert Opinion on Drug Metabolism & Toxicology 2009; 5(9): 1113 doi: 10.1517/17425250903124363
|
| 14 |
H. MIWA, M. SASAKI, T. FURUTA, T. KOIKE, Y. HABU, M. ITO, Y. FUJIWARA, T. WADA, A. NAGAHARA, M. HONGO, T. CHIBA, Y. KINOSHITA. Efficacy of rabeprazole on heartburn symptom resolution in patients with non‐erosive and erosive gastro‐oesophageal reflux disease: a multicenter study from Japan. Alimentary Pharmacology & Therapeutics 2007; 26(1): 69 doi: 10.1111/j.1365-2036.2007.03350.x
|
| 15 |
Alan B. R. Thomson. Standard doses of the oral proton pump inhibitors are clinically equivalent: A comparison. Current GERD Reports 2007; 1(4): 223 doi: 10.1007/s12171-007-0022-0
|
| 16 |
P. W. Weijenborg, F. Cremonini, A. J. P. M. Smout, A. J. Bredenoord. PPI therapy is equally effective in well‐defined non‐erosive reflux disease and in reflux esophagitis: a meta‐analysis. Neurogastroenterology & Motility 2012; 24(8): 747 doi: 10.1111/j.1365-2982.2012.01888.x
|
| 17 |
Debora Chiodi, Yoshihiro Ishihara. The role of the methoxy group in approved drugs. European Journal of Medicinal Chemistry 2024; : 116364 doi: 10.1016/j.ejmech.2024.116364
|
| 18 |
M. MIKI, K. ADACHI, T. AZUMI, K. KOSHINO, K. FURUTA, Y. KINOSHITA. A comparative study of intragastric acidity during post‐breakfast and pre‐dinner administration of low‐dose proton pump inhibitors: a randomized three‐way crossover study. Alimentary Pharmacology & Therapeutics 2006; 24(10): 1445 doi: 10.1111/j.1365-2036.2006.03140.x
|
| 19 |
K. R. DEVAULT. Review article: the role of acid suppression in patients with non‐erosive reflux disease or functional heartburn. Alimentary Pharmacology & Therapeutics 2006; 23(s1): 33 doi: 10.1111/j.1365-2036.2006.02798.x
|
| 20 |
Claudine M. Baldwin, Susan J. Keam. Rabeprazole. Drugs 2009; 69(10): 1373 doi: 10.2165/00003495-200969100-00007
|
| 21 |
Gastroesophageal reflux disease: drug therapy. Revista da Associação Médica Brasileira (English Edition) 2011; 57(6): 603 doi: 10.1016/S2255-4823(11)70124-2
|
| 22 |
Akihito Nagahara, Tsuyoshi Suzuki, Naoyoshi Nagata, Nozomu Sugai, Yoshiaki Takeuchi, Kouichi Sakurai, Masaki Miyamoto, Kazuhiko Inoue, Junichi Akiyama, Katsuhiro Mabe, Ichiro Konuma, Tomoari Kamada, Ken Haruma. A multicentre randomised trial to compare the efficacy of omeprazole versus rabeprazole in early symptom relief in patients with reflux esophagitis. Journal of Gastroenterology 2014; 49(12): 1536 doi: 10.1007/s00535-013-0925-8
|
| 23 |
Motoyasu Kusano, Naohito Shirai, Kanako Yamaguchi, Michio Hongo, Tsutomu Chiba, Yoshikazu Kinoshita. It Is Possible to Classify Non-erosive Reflux Disease (NERD) Patients into Endoscopically Normal Groups and Minimal Change Groups by Subjective Symptoms and Responsiveness to Rabeprazole—A Report from a Study with Japanese Patients. Digestive Diseases and Sciences 2008; 53(12): 3082 doi: 10.1007/s10620-008-0290-2
|
| 24 |
Brigida Barberio, Pierfrancesco Visaggi, Edoardo Savarino, Nicola de Bortoli, Christopher J. Black, Alexander C. Ford. Comparison of acid‐lowering drugs for endoscopy negative reflux disease: Systematic review and network Meta‐Analysis. Neurogastroenterology & Motility 2023; 35(1) doi: 10.1111/nmo.14469
|
| 25 |
Takuma Kagami, Mitsushige Sugimoto, Hitomi Ichikawa, Shu Sahara, Takahiro Uotani, Mihoko Yamade, Yasushi Hamaya, Moriya Iwaizumi, Satoshi Osawa, Ken Sugimoto, Hiroaki Miyajima, Takahisa Furuta. One-day front-loading with four doses of rabeprazole followed by a standard twice-daily regimen provides sufficient acid inhibition in extensive metabolizers of CYP2C19. European Journal of Clinical Pharmacology 2015; 71(12): 1467 doi: 10.1007/s00228-015-1941-9
|
| 26 |
Joaquim Prado P. Moraes-Filho, Tomas Navarro-Rodriguez, Ricardo Barbuti, Jaime Eisig, Decio Chinzon, Wanderley Bernardo. Guidelines for the diagnosis and management of gastroesophageal reflux disease: an evidence-based consensus. Arquivos de Gastroenterologia 2010; 47(1): 99 doi: 10.1590/S0004-28032010000100017
|
| 27 |
Kwong Ming Fock, Nicholas J Talley, Ronnie Fass, Khean Lee Goh, Peter Katelaris, Richard Hunt, Michio Hongo, Tiing Leong Ang, Gerald Holtmann, Sanjay Nandurkar, San Ren Lin, Benjamin CY Wong, Francis KL Chan, Abdul Aziz Rani, Young‐Tae Bak, Jose Sollano, Lawrence KY Ho, Sathoporn Manatsathit. Asia‐Pacific consensus on the management of gastroesophageal reflux disease: Update. Journal of Gastroenterology and Hepatology 2008; 23(1): 8 doi: 10.1111/j.1440-1746.2007.05249.x
|
| 28 |
E. S. LEE, N. KIM, S. H. LEE, Y. S. PARK, J. W. KIM, S. H. JEONG, D. H. LEE, H. C. JUNG, I. S. SONG. Comparison of risk factors and clinical responses to proton pump inhibitors in patients with erosive oesophagitis and non‐erosive reflux disease. Alimentary Pharmacology & Therapeutics 2009; 30(2): 154 doi: 10.1111/j.1365-2036.2009.04021.x
|
| 29 |
Y. Kinoshita, K. Ashida, M. Hongo. Randomised clinical trial: a multicentre, double-blind, placebo-controlled study on the efficacy and safety of rabeprazole 5 mg or 10 mg once daily in patients with non-erosive reflux disease. Alimentary Pharmacology & Therapeutics 2011; 33(2): 213 doi: 10.1111/j.1365-2036.2010.04508.x
|
| 30 |
B. Al-Judaibi, N. Chande, G.K. Dresser, N. Sultan, J.C. Gregor. Gastric Acid-Related Diseases: Focus on Esomeprazole. Clinical Medicine Insights: Therapeutics 2010; 2: CMT.S4500 doi: 10.4137/CMT.S4500
|
| 31 |
Jing Sun, Yao-Zong Yuan, Xiao-Hua Hou, Duo-Wu Zou, Bin Lu, Min-Hu Chen, Fei Liu, Kai-Chun Wu, Xiao-Ping Zou, Yan-Qing Li, Li-Ya Zhou. Esomeprazole regimens for reflux symptoms in Chinese patients with chronic gastritis. World Journal of Gastroenterology 2015; 21(22): 6965-6973 doi: 10.3748/wjg.v21.i22.6965
|
| 32 |
J. HORN. Review article: understanding the pharmacodynamic and pharmacokinetic differences between proton pump inhibitors – focus on pKa and metabolism. Alimentary Pharmacology & Therapeutics Symposium Series 2006; 2(2): 340 doi: 10.1111/j.1746-6342.2006.00065.x
|
| 33 |
Sanjay Nandurkar. Frequency scale symptoms for gastroesophageal reflux disease (Frequency Scale for Symptoms of GERD) predicts need for addition of prokinetics to proton pump inhibitor therapy. Journal of Gastroenterology and Hepatology 2008; 23(8pt1): 1165 doi: 10.1111/j.1440-1746.2008.05517.x
|
| 34 |
Ravi Vachhani, Gregory Olds, Vic Velanovich. Esomeprazole: a proton pump inhibitor. Expert Review of Gastroenterology & Hepatology 2009; 3(1): 15 doi: 10.1586/17474124.3.1.15
|
| 35 |
Gastroesophageal reflux disease: drug therapy. Revista da Associação Médica Brasileira 2011; 57(6): 603 doi: 10.1016/S0104-4230(11)70124-5
|
| 36 |
M R Craven, L Kia, L C O’Dwyer, E Stern, T H Taft, L Keefer. Systematic review: methodological flaws in racial/ethnic reporting for gastroesophageal reflux disease
. Diseases of the Esophagus 2018; 31(3) doi: 10.1093/dote/dox154
|
| 37 |
Toru Hiyama, Keitaro Matsuo, Yuji Urabe, Tatsuma Fukuhara, Shinji Tanaka, Masaharu Yoshihara, Ken Haruma, Kazuaki Chayama. Meta‐analysis used to identify factors associated with the effectiveness of proton pump inhibitors against non‐erosive reflux disease. Journal of Gastroenterology and Hepatology 2009; 24(8): 1326 doi: 10.1111/j.1440-1746.2009.05879.x
|
| 38 |
Motoyasu Kusano, Shikou Kuribayashi, Osamu Kawamura, Yasuyuki Shimoyama, Hiroko Hosaka, Atsuto Nagoshi, Hiroaki Zai, Masatomo Mori. A Review of the Management of Gastric Acid-Related Diseases: Focus on Rabeprazole. Clinical Medicine. Gastroenterology 2011; 4: CGast.S5133 doi: 10.4137/CGast.S5133
|
| 39 |
Syed Fahim Shah, Sohail Aziz Paracha, Waheed Ullah, Iqbal Muhammad, Somaid Iqbal, Aisha Gul, Mudassir Hussain, Hafiz Ullah, Sadir Zaman. Success of 14-day triple and quadruple therapy for the control of Helicobacter pylori infections in Kohat district. Drug Target Insights 2022; 16(1): 49 doi: 10.33393/dti.2022.2481
|